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INTRODUCTION    
 Guillain Barre Syndrome (GBS) is an acute, autoimmune, 
frequently severe, polyradiculoneuropathy. GBS affects all ages and it 
has a slight male preponderance. It is a symmetrical, predominantly 
motor, flaccid and areflexic paralysis with a clinical progression of the 
disease usually for a period of 4 weeks. 
GBS has an incidence of around 0.4-1.9 per one lakh population. 
The neuropathic symptoms are preceded by mild upper respiratory or 
gastrointestinal symptoms in most of the cases by 1-3 weeks in 50-70% 
of cases. Recently enteric organisms Campylobacter jejuni serological 
studies are done and it is identified as the causative organism in a small 
proportion of cases.  Multiple cranial nerve palsy involving facial, bulbar 
and ocular muscle has been reported in 10-60% of cases with papilledema 
being uncommon. Respiratory failure occurs in 10-30% of cases. 
 
GBS is a self limiting disorder associated with recovery in upto 
70% of cases but the morbidity and mortality is bestows is also a concern 
as the sequelae of the disease is associated with significant motor 
handicap in up to 7% of cases. Mortality usually reaches up to 14% in 
few studies. 
GBS subtypes are recognized on the basis of electro diagnostic and 
pathologic distinctions and it includes acute inflammatory demyelinating 
polyneuropathy (AIDP), the most common variant, followed by two 
axonal variants –Acute motor sensory axonal neuropathy (AMSAN) and 
Acute motor axonal neuropathy(AMAN). Regional variants include 1. 
Miller Fisher syndrome,2. Pandysautonomia, 3.pure sensory syndrome, 
ophthalmoplegia with anti-GQ1b antibodies, 4.GBS with severe bulbar 
and facial palsy. 
Cerebrospinal fluid analysis typically reveals ‘albumino - 
cytological dissociation. Nerve conduction studies shows reduced 
conduction velocity with conduction block, accompanied with increased 
distal latency. Prolonged or absent F waves in two or more motor nerves 
is characteristically seen. Sensory nerve conduction delay occurs in up to 
60% of cases. 
Immunomodulation is the treatment of choice, done with either 
plasmapharesis or intravenous immunoglobulin (IVIG) with both modes 
having equal efficacy in terms of treatment. 
AIM AND OBJECTIVES OF STUDY 
The purpose of this study is about the clinical profile with electro 
diagnostic features of GBS  in  a South Indian population  admitted at a 
tertiary care Centre in Madras Medical College, to correlate the clinical 
and electro diagnostic features with disability of the disease and thereby 
to identify the poor prognostic clinical and nerve condition features in a 
much earlier course of the disease so that ,those groups can be treated and 
monitored more scrupulously during the course of the disease and hence 
attenuate the morbidity and mortality associated with the disease.  
REVEIW OF LITERATURE  
GENERAL CONSIDERATION 
Guillain-Barre Syndrome (Landry-Guillain-Barre-Strohl Syndrome) 
also known as acute inflammatory demyelinating polyneuropathy, (AIDP) 
is a common cause of acute or sub-acute generalized paralysis with close 
competence to Polio at a time in history
1
. It has a worldwide distribution 
without much seasonal variation, though certain studies show an 
increased incidence of the disease in winter and few temperate countries 
show an increased trend in the rainy months
1-5
. Respiratory and gastro 
intestinal infections can occur at the offset the disease in up to 70% of 
cases
7
. They are followed by neurological symptoms and signs 1-3 weeks 
or sometimes even longer in around 60% of cases.Though the infections 
are trivial but often febrile. Other antecedent events associated wi th GBS 
are immunization at one point or another and can even sometimes occur 
as coincidence though details are not  
available. Few microbes are associated with GBS. Recent studies 
can demonstrate serological markers of enteric organisms such as 
Campylobacter jejuni associated with causation of the disease but has 
been proved as a causative agent only in small proportion of the cases up 
to 32%
10
. The clinical symptoms include that of watery diarrhea and 
abdominal cramping. It produces motor axon degeneration associated 
with increased anti-GM1 antibodies and often shows delayed but 
incomplete recovery of GBS
11
. Other organisms implicated are viruses 
like Cytomegalovirus which is associated with sensory and cranial nerve 
dysfunction  and elevated anti GM2 antibodies, Epstein-Barr-Virus, 
Human immunodeficiency Virus, bacteria’s such as Mycoplasma 
pneumonia and Borrelia burghdoferi. Lymphomas such as Hodgkin 
Lymphoma and exposure to thrombolytic agents have been rarely 
associated with GBS
5
. Vaccines such as the outdated anti-rabies vaccine
23
 
developed with the nervous tissue and the swine influenza vaccine, also 
known as the New Jersey vaccine given in late 1976  
showed a slight increase in the number of GBS cases then
21-28
. 
Trauma and surgery are very rarely know to precede the neurological 
symptoms of GBS but clear cut causal relation is yet to be proved. GBS 
has also been reported along with autoimmune conditions like systemic 
lupus erythematosus very rarely
19
. Other much rarer association include 
carcinoma lung, paraproteinemia and sarcoidosis.  GBS has also been 
reported in the postpartum period. 
HISTORY OF GBS 
The first report of generalized paralysis was found in the 
description given by Wardrop and Ollivier in the year 1934. Later in the 
year 1859 Landry reported a case of acute ascending motor paralysis 
associated with respiratory failure culminating in death. It was the French 
neurologist trio of Guillaine, Barre and Strohl described the acute flaccid 
paralysis that developed in two French soldiers and found to resolve 
spontaneously without any treatment  
or complication. They even reported the albumino-cytological 
dissociation found in the CSF analysis of those patients which was quiet 
unique compared to the flaccid paralysis of Polio. The pathophysiology 
of GBS was described by Haymaker and Kernohan in the year 1949 who 
emphasized the edema of the nerve roots during the initial stages of the 
disease. In the year 1969 the hallmark of the disease was studied and 
found to be perivascular mononuclear inflammatory infiltration of the 
nerve roots which was described extensively by Asbury, Arnason and 
Adams
1-5
. Though the disease has no specific diagnostic tests it remains a 
descriptive disorder characterized by rapidly progressive weakness 
usually symmetrical involving both legs and arms, with hyporeflexia or 
areflexia and a flaccid type of paralysis. More recently complement 
deposition of the myelin sheath have been demonstrated as the earliest 
clinical event taking place. 
 
 
INCIDENCE 
The incidence of GBS ranges from 0.4-1.8 per one lakh population 
per year
6-10
. Most studies found a male preponderance of the disease with 
a male is to female ratio of 3:2. Regarding the seasonal variation, is one 
of the conspicuous reports from China with axonal variants in the rural 
rice fields during the years of 1991-1992. The disease is prevalent in both 
extremes of the age group with mean age of the population being 44.  
PATHOPHYSIOLOGY 
Several studies demonstrate the autoimmune nature of the disease 
process with the cell mediated immunologic reactions directed against the 
peripheral nerves. Experimentally induced peripheral nerve disease also 
known as experimental allergic neuritis or EAN was demonstrated by 
Adams et al in animals 2 weeks after immunization
14
. The basic protein 
designated as P2 found only in the peripheral nerves was demonstrated by 
Brostoff  
 
 
 
 
and his colleagues. High levels of soluble interleukin IL-2 receptors 
shed from the activated T cells and IL-2 itself found in high levels in 
GBS patients have been found out. It involves all the cell mediated, 
humoral and complement mediated immune system in the pathogenesis of 
the disease process
32
. Postulated immunopathogenesis of GBS which is 
associated with Campylobacter jejuni infections has been demonstrated 
below in the pictorial representation of the disease pathophysiology. The 
glycoconjugates on the C.jejuni cross reacting with the ganglioside of the 
Schwann cell surface receptors and adjacent peripheral myelin sheath are 
recognized by the B cells and these B cells along with those activated by 
the T cell and independent of T cell activation secrete the IgG and IgM 
antibodies respectively. CD4 cells also take part in this process of T 
helper cell action by the protein of C.jejuni presented by the antigen 
presenting cells. The crucial event taking place is the escapade of the 
activated B cells from the gut Peyers patches into the regional 
lymphnodes. Along with the activated T cells, the activated B cells break 
the blood nerve barrier allowing the deposition of auto antibodies into the 
myelin sheath and the perivascular area. This is characterized by edema 
between the myelin lamellae and vesicular disruption demonstrated in the 
the form of circular blebs along the outer surface of the myelin sheaths. 
The membrane attack complex consisting of the C5b-C9 allows the 
calcium entry into the myelin sheaths along with other mediators of 
myelin damage such as the TNF-Tumor necrosis factor
33
. 
  
 
 
 
 
 
 
 
I. ANTIGANGLIOSIDE ANTIBODIES 
Various ganglioside antibodies like GM1, GM1b, GM2, GD1a, 
GD1b, GQ1b, GT1a
32-35
 etc, have been distributed in a specialized 
fashion in the nerve sheaths known as lipid rafts. These antibodies are 
associated with variants of GBS. GM1 and GD1a antibodies are 
associated with pure motor or axonal variants whereas GD3, GT1a and 
GQ1b are associated with the Miller Fisher variant. Glycolipid directed 
antibodies and even antibodies to the peripheral nerves have been 
identified. In few variants of GBS such as the sensory motor variant the 
antibody target is yet to be identified 
II. MOLECULAR MIMICRY AND CROSS REACTIVITY 
The immune response towards the non-self antigens are directed or 
misdirected towards the host nerve tissue because of a epitope 
resemblance known as molecular mimicry
38
. Glycoconjugates present in 
the neural tissue are the targets. To be more specific the gangliosides 
which are the complex glycosphingolipids with sialic acid residues and 
participates in cellular interaction is mimicked by the 
lipooligosaccharides which are expressed by C.jejuni. Ganglios ides are 
present in abundance in the plasma membrane of cells and also in the 
human nervous tissue at the Nodes of Ranvier. GM1 antibodies are the 
most common type directed against the gangliosides of the nervous tissue 
in C. jejuni infections
42
. These antibodies are present in 20-50% of cases. 
Sialic acid residues of these pathogenic C.jejuni can also trigger the 
dendritic cells and hence the toll like receptors and resulting in B cell 
activation and hence humoral autoimmunity. H.influenza is even known 
to demonstrate molecular mimicry strategies. 
Few reports of the purified bovine brain gangliosides which are 
used in the treatment of various neuropathic disorders are shown to inflict 
GBS in few group of patients in Europe and these patients demonstrate 
high level of anti GM1 antibodies targeted against the Nodes of Ranvier.  
 
 
 
 
 
 
 
 
III. COMPLEMENT MEDIATED ACTIVATION 
Complement activation have been shown to produce nerve damage 
by the anti GM1 antibodies  around the Nodes of Ranvier
86
, disrupting 
the sodium channels resulting in conduction blocks at these sites
56-57
. 
Experimental models reveals the similarity of complement activation to 
that of a alpha latrotoxin like effect which is associated with dramatic 
release of acetylcholine and neurotransmitter depletion at these sites and 
nerve muscle paralysis. Interestingly these neurotoxic effects can be 
inhibited by the immunoglobulins and complement inhibitors like 
eculizumab
75
. 
         Miller Fisher Syndrome is associated with Anti GQ1b IgG 
antibodies which are found in 90% of these cases
40,73
. These antibodies 
are found early in the course of the disease and also are specific to this 
particular variant unless the other variants involve the extra ocular motor 
nerve involvement. The extra ocular nerves are abundant in the GQ1b 
antibodies compared to other organs. 
         Though these observations are strong enough to suggest an 
autoimmune basis as a strong pathogenic cause in GBS yet are  found to 
be inconsistent. This is because antibodies are also demonstrated against 
the Schwann cells and nerve growth cone regions but these antibodies 
were not able to produce disease when direct passive transfer was done to 
a naïve host. On the other hand trans placental transfer of antibodies 
resulting in GBS in the fetus has also been demonstrated
51
. 
            Complement mediated activation occurs first which results in 
vesicular disintegration of the myelin sheath and macrophage recruitment 
at these sites thus producing collateral damage to the axon and myelin 
sheaths. Anti GD1a antibodies found in AMAN variant are deposited in 
the large motor axons and sparing the sensory roots as well although both 
motor and sensory nerves express the gangliosides.  
             Conduction block is the hallmark of demyelinating forms of GBS 
resulting in flaccid paralysis and sensory disturbances. Since axonal 
connections remain intact the recovery can take place rapidly as 
remyelination can occur
69
. But once axonal degeneration sets in the 
recovery rate can be much slower and secondary degenerative changes in 
the axons can result in residual disability. When axons have become 
degenerated and disintegrated demonstrable by the electrophysiological 
studies they much regenerate for recovery to occur. Other alternatives for 
regeneration includes collateral sprouting and reinnervation from motor 
axons can occur over a period of several months. 
 
CLINICAL FEATURES OF GBS 
GBS is rapidly evolving in nature with features of paresthesia and 
slight numbness of the toes and fingers being the earliest manifesta tion. 
However the areflexic motor paralysis evolving over a period of several 
day to 4 weeks is the course of the illness. The paralysis is ascending 
type and the patient characteristically describes their symptoms as 
rubbery legs. The legs are affected more than arms and both proximal and 
distal group of muscles are affected. The trunk, intercostal, neck and 
cranial muscles may be affected later
4-7
.  Facial paresis usually bilateral 
occurs in 50% of cases. Bulbar palsy and lower cranial nerve involvement 
are also frequently reported and associated with a delayed recovery or 
respiratory failure but these can be mistaken for brainstem ischemia
90
. In 
upto 5% percent of the patients the disease can result in total paralysis 
with respiratory failure occurring in a few days. Ocular nerve palsy with 
unreactive pupils can also occur. 
Pain and aching discomfort involving the hips, thighs and back or 
even diffusely over the entire spine can occur in about 50% of the cases 
and these are mistaken for back strain, lumbar disc disease and even other 
orthopedic diseases. Even few patients describe burning sensation 
involving the toes and fingers as their earliest symptom and it can 
become a persistent problem. Vibration and proprioception are reduced in 
the toes and fingers are reduced in the initial weeks  and touch-pressure 
vibration  tends to be more affected than pain and temperature.  
Deep tendon reflexes are reduced or absent and these findings are 
usually consistent. It is due to desynchronization of afferent impulses in 
reflex arc due to non – uniform demyelination.  Rarely only the ankle 
reflexes are lost in the initial weeks of the illness. The need for 
mechanical ventilation is associated with rapid progression of the disease 
process often associated with bulbar and facial muscle weakness. Fever 
and other constitutional symptoms are absent at the onset of the illness.  
Bladder dysfunction may occur in the much severe cases but it is 
usually transient in the initial weeks, if bladder dysfunction is found to be 
persistent than the diagnosis of GBS is to be doubted. The plateau of the 
disease is reached within a period of 4 weeks in most cases  
Disturbance in autonomic functions can occur even in milder cases 
of GBS and include the following features of sinus tachycardia, less often 
bradycardia, fluctuating blood pressure, facial flushing, loss of sweating 
or episodic profuse diaphoresis and cardiac arrhythmias. These symptoms 
infrequently persist for more than a week. Pain which is a dysesthetic 
pain can occur and its responsive to the usual pain medication. 
Lymphadenopathy and splenomegaly should prompt the diagnosis of viral 
infection associated with the disease. 
VARIANTS OF GBS 
 REGIONAL 
 Miller Fisher  syndrome  of ophthalmoplegia, ataxia and areflexia 
 Cervico-brachial –pharyngeal, associated with ptosis 
 Oculopharyngeal weakness 
 Predominantly paraparesis 
 Bilateral facial or abducens weakness with distal paresthesias 
 Ophthalmoplegia with GQ1b autoantibodies 
 
 
 FUNCTIONAL 
 Generalized ataxia without dysarthria or nystagmus 
 Pure sensory 
 Pure motor 
 Pan dysautonomia 
 Axonal 
 
ACUTE INFLAMMATORY DEMYELINATING 
POLYNEUROPATHY 
The most common variant of is Acute inflammatory    
Demyelinating polyneuropathy.  
Adults are most commonly affected 
90% occurs in western world 
Recovery is rapid usually  
Anti-GM1 antibodies is present in less than 50% 
Electrophysiological pattern shows a demyelinating pattern 
Schwann cells are affected first followed by widespread myelin 
damage, macrophage activation with lymphocytic infiltration and axonal 
damage. 
ACUTE MOTOR AXONAL NEUROPATHY (AMAN) 
This variant was described in detail by Feasby and his colleagues of 
an acute areflexic polyneuropathy with widespread and severe axonal 
degeneration
35
.  
Predominantly children and young adults are affected and has been 
prevalent in China and Mexico associated with rapid evolution of 
symptoms with very slow and poor recovery. 
Muscle atrophy becomes evident relatively early in the course of 
the disease.EMG shows numerous electrically in excitable motor nerves 
with signs of extensive denervation. Post mortem examinations show 
severe axonal degeneration in nerves and roots with minimal 
inflammatory changes. 
Complement depositions are prominent and macrophage has been 
demonstrated in the periaxonal space. Visser et al reported similar 
findings in a series of polyneuropathies from Holland. C.jejuni has been 
found to be associated with this type of GBS. Circulating antibodies to 
anti GM1 and anti GD1a have been demonstrated
31
. 
AMAN and AMSAN are equivalent to axonal GBS. Characterized 
by symmetric limb weakness, diffuse areflexia, facial and oropharyngeal 
muscle weakness and respiratory insufficiency. Extraocular muscles are 
typically spared 
Another variant of this illness has been described in several 
instances as an acute multifocal neuropathy with electrophysiologic 
motor conduction block where the reflexes are unaltered described by 
Caposso et al. A chronic form of this is termed as Multifocal motor 
neuropathy as it is commonly understood. 
It is not known whether the acute axonal polyneuropathy is a 
distinct entity of GBS or a variant39. These axonal neuropathies have 
poor response to immunetherapy
91
. Sometimes the electrically 
unexcitable nerves can be due to conduction block rather than axonal 
degeneration. The differential diagnosis of critical illness polyneuropathy 
and rarer entities of porphyric neuropathy and tick paralysis should be 
considered. 
ACUTE MOTOR SENSORY AXONAL NEUROPATHY(AMSAN) 
It is a motor sensory axonal variant of GBS with an annual 
incidence of 1.1 per one lakh population. First described by Feasby and 
his colleagues with severe disease progression
69
 . The disease process is 
characterized by quadriparesis with areflexia, distal sensory loss and 
respiratory failure. Upto 30-50% of cases have been reported in Asia and 
Latin America. Electrodiagnostic profile shows a diffuse loss of motor 
and sensory potentials with diffuse degeneration without evidence of 
demyelination. As with other types of GBS an infectious disease precedes 
the onset of limb weakness in majority of cases. It is associated with the 
following antibodies anti-GM1/GD1a/GM1b/GalNac-GD1a). 
MILLER FISHER VARIANT 
Is known for its classic triad of ophthalmoplegia, ataxia and 
areflexia which was described by C.Miller Fisher in 1956. 
Usually accounting for 5% of the GBS cases and in some studies 
upto 12% have been described .in south Asian population.  
Diplopia is the usual initial symptom  followed by limb or gait 
ataxia associated with mild sensory symptom, swallowing difficulties or 
proximal muscle weakness occurring in upto one half of the cases.  
Abducent nerve palsy is the first extraocular muscle palsy to occur 
and it may progess to complete ophthalmoplegia. Though ptosis is 
frequent, pupillary affliction is rare.  
Asymmetric limb involvement can occur in few cases with limb and 
gait ataxia which can be confused with cerebellar disease. CSF protein 
elevation is much less compared to the typical GBS. Adults and Children 
are affected with antibodies directed against GQ1b antibodies.  
Electrodiagnostic studies are variable with loss of sensory 
potentials, mostly demyelinating in nature sometime alternating with 
milder forms of axonal degeneration. May be confussed sometimes with 
encephalitis or cerebrovascular accidents. 
Motor nerve terminal blockade explains generalized weakness when 
associated with reversible failure of Acetylcholine release from 
presynaptic motor nerves. 
PURE MOTOR VARIANT 
Usually acute and progressive without sensory loss which has been 
reported in upto 18% in one case series. Predominantly involves the 
distal limbs but cranial nerve sparing and elevated anti GM1 titres and 
serology positive for C.jejuni infection. Course and recovery is similar to 
GBS.CSF proteins are usually elevated. 
Electrodiagnostic profile shows both axonal and demyelinating 
variety sometimes with marked axonal degeneration making recovery 
slower and associated with much more disability.  
Poliomyelitis, acute myasthenia gravis and tick paralysis can be 
considered as the differential diagnosis. 
PURE SENSORY VARIANT 
Relatively rare form of polyneuropathy with rapid onset large fiber 
sensory loss with the predominant symptom being sensory 
ataxia.Tremors, positive Romberg sign, pseudoathetosis and 
dysautonomia can occur. In severe cases sensory dysfunction may 
involve face and torso. CSF proteins are typically elevated and 
Electrodiagnostic study shows a demyelinating pattern 
Cervical myelopathy, Sjogren’s syndrome , Malignant and non 
malignant sensory neuropathy should be considered as the differential 
diagnosis. 
PURE DYSAUTONOMIC VARIANT 
Considered to be a much rarer variant of GBS. Initial symptoms 
being abdominal pain, vomiting , diarrhea and constipation with possible 
history of preceding viral infection 
Sometime gastroparesis with abdominal distention and ileau has 
been reported. Orthostatic hypotension associated with syncope, urinary 
urgency, retention, vasomotor instability and erectile dysfunction has 
been reported. 
Cardiac arrhythmias warrant intensive care monitoring of the 
disease process. Motor involvement is rare with milder forms of distal 
sensory symptoms and areflexia is usually present. 
 
Electrodiagnostic study is normal showing autonomic variability, 
tilt table testing, sympathetic skin response and abnormal sweat testing( 
QSART). Plateau is after a week and recovery is slow involving several 
months. 
PARAPARETIC VARIANT 
One of the types of regional variant with isolated leg weakness and 
areflexia. Typically upper limbs, cranial nerves and spinchters are spared 
with radicular pain being the most common symptom.  Electrodiagnostic 
study is demyelinating. MRI studies are done to rule out spinal cord 
disease such as disc disease or caudaequina syndrome.  
PHARYNGEAL CERVICAL BRACHIAL VARIANT 
Another regional variant affecting cervical, brachial and 
oropharyngeal muscles exclusively with antibodies against GT1a showing 
a higher level. May initially involve the pharyngeal and neck muscles 
with later spread to the limbs and lowerlimbs are typically spared.  
As it involves facial weakness with ptosis and ophthalmoparesis it 
can be mistaken for myasthenia gravis. Electrodiagnostic study shows a 
demyelinating pattern and the recovery is usually is late and incomplete.  
 
 
OTHER LESS COMMON VARIANTS 
 Bilateral foot drop with upper limb paresthesias 
 Acute ataxia without ophthalmoplegia 
 Facial diplegia or abducent palsies with distal paresthesias 
 Acral paresthesias with diminished reflexes in either arms or legs. 
 Isolated post infectious ophthalmoplegia. 
 
 
 
 
 
 
 
 
 
DIAGNOSTIC FEATURES OF ACUTE INFLAMMATORY 
DEMYELINATING POLYNEUROPATHY
12-13
 
 Progressive weakness of limbs  from mild paresis to complete paralysis 
 Generalized hypo or areflexia 
 Rapidly progressive motor weakness which reaches nadir in 2 weeks in 
50% , 3 weeks in 80%, 4 weeks in 90%\ 
 Mild to moderate sensory loss 
 Symmetrical limb involvement  
 Cranial nerve involvement-facial nerve paralysis which occurs in 50% 
and it is bilateral and asymmetrical, cranial nerves XII,X, III,IV,VI and 
XI can be involved 
 Recovery begins in 2-4 weeks 
 Autonomic dysfunction which includes tachycardia, arrhythmias, postural 
hypotension and vasomotor symptoms 
 Proceeding infections which may be gastrointestinal or respiratory tract 
infection. 
 Elevated CSF proteins 
 CSF counts which are <10 mononuclear cells/mm3 
 Nerve conduction studies show slowing or conduction block in 80% of 
cases 
 Nerve conduction velocity is reduces in 60% and it can be patchy 
 Distal motor latency increases and it can reach 3 times the normal value.\ 
 F-Waves indicate proximal NCV slowing. 
 NCV findings are normal in 15-20% of patients 
 No abnormalities can be found for several weeks in nerve conduction 
studies. 
FINDINGS REDUCING POSSIBILITY OF DIAGNOSIS  
 When asymmetrical weakness is present 
 Bladder and bowel symptoms which fail to resolve 
 Severe bladder and bowel involvement at the initiation of disease 
 Greater than 50 mononuclear cells /mm3 in CSF 
 Well demarcated sensory level 
 
EXCLUSION CRITERIA 
Other causes of acute neuromuscular weakness like myasthenia 
gravis, botulism, poliomyelitis, toxic neuropathy. Abnormal CSF 
cytology suggesting carcinomatous invasion of the nerve roots. 
LABORATORY FINDINGS 
CSF findings which are distinctive and consisting of elevated 
protein which may reach up to 100-1000mg/dl without pleocytosis. CSF 
may be normal upto 48 hours; it is only by the end of  first week when the 
protein levels are elevated. The cell count may reach upto 10-100 cells 
per microliter. Persistent CSF pleocytosis suggests alternate diagnosis 
like viral myelitis, unrecognized HIV infection, leukemia or lymphomas 
or even neurosarcoidosis. The number of cells reduces rapidly in a matter 
of 2-3 days. The CSF proteins are normal during the first few days of 
symptoms but begin to rise later and reaching a peak in 4-6 weeks. The 
increase in proteins reflects a widespread inflammatory disease of nerve 
roots, but higher values does not have any prognostic significance. The 
CSF proteins may remain normal in few cases of GBS all throughout the 
disease. It particularly occurs in patients with Fisher syndrome or other 
axonal forms of GBS, where the CSF proteins may be normal or only 
slightly elevated. 
NERVE CONDUCTION STUDY ABNORMALITIES 
The most frequent early electrodiagnostic feature of GBS are 
reduction in the amplitude of muscle action potentials, slowing of 
conduction velocity and conduction blocks. Prolongation of distal 
latencies and absent F waves which reflect involvement of proximal 
nerve roots reflecting focal demyelination. Delayed H-reflex is almost 
always present. Disordered conduction is the hallmark of the disease 
which may be present more prominently as the disease progresses but 
widespread axonal damage even early in the course of the disease always 
been a poor prognostic factor. Acute GBS patients shows gadolinium 
enhancement of the cauda equine roots on magnetic resonance imaging 
and it can also prove as a diagnostic factor in complicated cases.  
METABOLIC ABNORMALITIES 
Liver function abnormalities have been found to be abnormal in 
fewer than 10 percent of the patients which indicates a recent or ongoing 
viral hepatitis probably due to CMV or EBV infections. T wave and other 
ECG changes of minor degree are reported frequently but these are only 
temporary. The Erythrocyte sedimentation rate is normal and is elevated 
only when there is additional process of infection, neoplastic or 
autoimmune factor which can coexist with GBS like SLE.  
Hyponatremia occurs in a small proportion of the cases after the 
first week especially in patients on mechanical ventilation and it is 
usually attributable to the syndrome of inappropriate antidiuretic  
hormone secretion ( SIADH) but the atrial natriuretic effect also 
contributes to the natriuretic effect. Hyponatremia was noted in upto 48% 
of cases in one case series. Pseudohyponatremia  from the intravenous 
immunoglobulin administration have also been described in few studies. 
Pseudo hyponatremia usually occurs because of increase protein and lipid 
concentration during the measurement of sodium using ion selective 
electrodes. The indirect analytical methods usually exclude the lipids and 
proteins occupying the plasma sample and thereby produce a falsely low 
sodium levels and it can solved by using the direct ion selective 
electrodes. The intravenous immunoglobulins are liable to cause 
hyponatremia due the large amount of proteins it carries. But this cannot 
be the only reason as true hyponatremia has also been demonstrated using 
the direct ion selective electrodes. This true hyponatremia has been 
attribute to osmotic translocation of water from intracellular to 
extracellular space mediated by increase in intravascular osmolality due 
to sucrose based immunoglobulin prepartions. Diabetes insipidus is rare 
and it is usually unexplained. High rates of proteinuria and 
glomerulonephritis have been reported in a few studies and the cause is 
usually unknown. 
Hypokalemia has also been reported in few cases of GBS when the 
diagnosis can be really perplexing as both can cause flaccid paralysis. 
Hypomagnesemia has also been reported in GBS and it can occur due to 
the process of plamapharesis which can remove magnesium from the 
plasma pool. 
DIFFERENTIAL DIAGNOSIS OF GBS 
GBS is the most common type of acute generalized polyneuropathy 
as well as the most frequently evolving and even potentially fatal form of 
polyradiculoneuropathy. It is the form of polyradiculoneuropathy which 
can bring the patient to the brink of death and even produce respiratory 
failure within days to weeks. But there are other neurologic mimickers 
which can even produce such degree of flaccid paralysis and respiratory 
failure. 
The most important problem is that of spinal cord disease to 
differentiate from GBS using a definite sensory level  and there is marked 
bladder and bowel involvement. The spinal cord disease can be usually 
multifactorial and the usual preceding factors can be that of trauma or 
even long standing lower back ache. The preceding viral infection in 
transverse myelitis should be kept in mind as even GBS has the same 
preceding cause but the major sphincter involvement and the disease can 
be proven by MR imaging which can be associated with significant 
demyelination. There can be certain confounding factors like loss of 
tendon reflexes which can occur in the initial stages of the spinal cord 
disease due to spinal shock. 
Necrotizing myelopathy which is quite common in the tropical 
regions can even mimic GBS which can be associated with absent tendon 
reflexes due to extensive destruction of the grey matter of the spinal cord. 
Still more confusing factor is the early and transient urinary retention 
which can occur in smaller portion of GBS patients, but bladder and 
bowel involvement is not so extensive as in spinal cord diseases which 
helps to differentiate between the two. 
Another common spinal cord disease which can be confused with 
GBS include cervical myelopathy. In GBS there is generalized paralysis 
with facial and respiratory muscle involvement. The fingertips are 
paresthetic once the sensory system is involved and ascended to the calf 
level. Sensory loss involving the periphery and the trunk occurs rarely in 
early course of the disease but the reflexes are lost invariably in all limbs 
in comparison to cervical myelopathy which can be brisk. 
Poliomyelitis is another differential diagnosis which can be 
considered and compared with GBS as there is predominant motor 
involvement in either cases. Other viral muscular paralysis which occurs 
in the western world due to the west nile virus and the enterovirus are 
notable examples other than polio. These infections are viral and are 
usually accompanied with significant findings of fever, meningo-
encephalitis, early and significant pleocytosis in the spinal fluid and 
motor paralysis particularly with rather asymmetric involvement  
Carcinomatous meningitis is another entity should be considered 
which is characterized by sub acute and symmetric involvement but more 
importantly involves the distal musculature and producing distal 
weakness more than proximal weakness. Comparing the proximal and 
distal group of muscles there is usually irregular involvement and the 
facial muscles are usually spared in comparison with Guillaine Barre 
syndrome. The limb involvement is also not simultaneous and symptoms 
occur in a one limb following the other and is due to the neoplastic 
infiltration of nerve roots. Sciatica may be an accompanied finding in 
either cases but radicular pain is unusual in GBS. Spinal fluid analysis for 
the carcinomatous cells solves the dispute and is diagnostic for 
carcinomatous meningitis. 
Another interesting differential diagnosis for generalized GBS with 
ophthalmoparesis or Fisher variant form of GBS is Basilar artery 
thrombosis. The differentiating features include brisk reflexes with 
Babinski sign being positive in the case of basilar artery thrombosis in 
comparison with GBS which is characterized by reactive pupils, areflexia 
and F wave abnormalities in the latter. 
Acute myasthenia gravis is another important differential diagnosis 
for GBS with ophthalmoparesis or the Fisher variant which is 
characterized by ophthalmoplegia where as myasthenia gravis include 
ptosis, ophthalmoplegia , bulbar paralysis and respiratory muscle 
paralysis. The important feature to differentiate is absence of sensory 
symptoms as wells as the tendon reflexes which are impaired. The 
mandibular muscles are very rarely involved in GBS in comparision with 
myasthenis gravis where the excercised jaw hangs open. Neostigmine 
improves the condition of myasthenia gravis whereas it has no role in 
GBS. 
Botulism may also simulate GBS but there is usually bradycardia 
which is unusual for GBS. Tick paralysis, which affects the pediatric  
population of the western world but can affect both the young and old in 
the eastern part of the world is nearly impossible to differentiate from 
GBS unless one find the tick. Both share ascending paralysis and 
sometimes can even produce ataxia and ophthalmoplegia but sensory loss 
is not a feature of tick paralysis and the CSF protein invariably remains 
the same.  
Few cases of shellfish or reef fish consumption contaminated with 
saxitoxin, ciguatoxin, or even tetrodotoxin which occurs in neurotoxic 
shellfish poisoning can produce acute facial-brachial paresthesias, 
weakness, tachypnea and even iridoplegia which may last for a few days 
and can mimic GBS with generalized weakness or the Fisher variant.  
Neuromuscular disorders in critically ill patients with systemic 
comorbid medical condition makes it difficult to distinguish it from GBS. 
Some of the following includes polyneuropathy in the critically ill, 
metabolic causes like the accelerated neuropathy of renal failure which is 
seen predominantly in the diabetic population who receive peritoneal 
dialysis or acute hypophosphatemia induced by hyperalimentaion can 
also mimic GBS. Drug induced polymyopathy due to drugs like steroids 
and the prolonged effects of neuromuscular blocking agents which may 
get accumulated in certain conditions like renal failure and acidosis can 
also simulate GBS. episodic porphyria are painful polyradiculopathy 
associated with paralysis. 
 
CRITICAL ILLNESS POLYNEUROPATHY 
It is an acute or sub acute symmetrical polyneuropathy which 
occurs in critically ill and septic patients especially in patients with 
multiorgan failure. It complicates weaning in mechanically ventilated 
patients even when the multiorgan failure is brought under control. The 
similarities with GBS include predominant motor paralysis and can 
include few electrophysiological abnormalities like conduction blocks 
and can even result in respiratory failure. Sensory symptoms can occur in 
various degrees but is usually mild. But cranial nerve involvement is 
rarer as is the autonomic dysfunction which seldom occurs. The EMG 
findings shows early denervation and normal CSF distinguish it from the 
demyelination associated with GBS. There are no inflammatory nerve 
changes. But the axonal form of GBS and critical illness neuropathy 
bears close resemblance and the confounding factors of drugs and 
nutritional deficiencies are attributable to the critical illness neuropathy. 
Many mediators of inflammation particularly the tumor necrosis factor 
has been implicated in the causation of critical illness neuropathy. 
Another close differential diagnosis is acute quadriplegic myopathy 
which can occur in the critically ill. It has been attributed due to high 
dose of steroids and neuromuscular blocking agents but it can be 
differentiated using serum creatine kinase which may reach concentration 
up to several thousand units and the electro diagnostic studies reveal a 
unique pattern producing degeneration of myofilaments in all the 
muscles. 
ACUTE UREMIC POLYNEUROPATHY 
The well-known chronic sensory neuropathy associated with 
chronic kidney disease can sometimes mimic GBS by its accelerated 
process culminating in sub-acute and acute weakness of muscles. But it 
occurs predominantly in diabetic patients with end stage renal failure and 
who has been treated with peritoneal dialysis. In some ways the illness 
simulates GBS like generalized weakness and paresthesia predominantly 
distal. Change to hemodialysis produces little effect but renal 
transplantation is curative. The electrophysiological pattern mimics GBS 
producing a demyelinating pattern but there are no conduction blocks. 
The CSF proteins are also elevated. Few case series have reported 
features both clinical and electrophysiological quiet indistinguishable 
from GBS and even some produce rapid clinical response to plasma 
exchange or gamma globulin infusion. 
DIPHTHERITIC POLYNEUROPATHY 
Corynebacterium diphtheria produces an exotoxin paralyses 
pharyngeal and laryngeal muscles within 1-2 weeks after the onset of 
infection and produces blurring of vision due to paralysis of 
accommodation. It produces a polyneuropathy beginning 5 to 8 weeks, 
acute or subacute limb weakness with paresthesias and distal loss of 
vibratory and position sense. The weakness involves the extremities 
predominately. After a few days the patient becomes bedridden and it can 
even produce respiratory muscle paralysis. The CSF protein is usually 
elevated 50-200 mg/dl. The pharyngeal infections are associated with 
cardiomyopathy and severe polyneuropathy with respiratory paralysis. It 
usually produces segmental demyelination without inflammatory changes 
involving the sensory roots and sensory ganglia. Treatment is with 
Diphtheria antitoxin given within 48h of onset of infection but is of little 
value when polyneuropathy develops. The prognosis is usually excellent 
when respiratory paralysis is overcome. 
PORPHYRIC POLYNEUROPATHY 
It is a severe rapidly advancing symmetrical and motor 
polyneuropathy often with abdominal pain and psychosis and 
convulsions. It is inherited as an autosomal dominant trait. The metabolic 
defect is present in the liver and is due to the increased production and 
increased urinary excretion of delta amino levulinic acid. The peripheral 
and the central nervous system is affected usually in the variegate type of 
porphyria and is associated with marked skin sensitivity to light and 
trauma. The first study was made by Waldenstrom in 1937. The classic 
symptom is moderate to severe colicky pain of the abdomen. Frequently 
associated with constipation and ileus and vomiting. The d isease is 
characterized by recurrent attacks and precipitated by sulfonamides, 
griseofulvin, estrogen, barbiturates, phenytoin and succinimide 
anticonvulsants. These drugs should be avoided in patients with 
porphyria and seizure disorder. The neurologic manifestation typically 
involves motor nerves more severely than the sensory nerves. The 
symptoms usually involve the feet and ascend upward. The proximal 
muscles are more often involved with loss of knee jerk with preservation 
of ankle jerk. Facial palsy, dysphagia and ocular palsy occurs in severe 
cases. The symptoms vary from mild to severe fatal respiratory paralysis 
or cardiac paralysis. Confusion, delirium, visual defects and convulsion 
occur and can progress to severe neuropathy. Autonomic symptoms like 
tachycardia and hypertension are present in the acute phase of the 
disease. The prognosis is usually excellent. To summarize it is 
characterized by relapsing nature, acute onset, and abdominal pain, 
psychotic symptoms with predominant motor neuropathy of ten with 
bibrachial distribution of weakness, truncal sensory loss and tachycardia.  
The pathologic finding is insignificant ,rarely associated with 
demyelination. Diagnosis is confirmed by demonstration of large amounts 
of porphobilinogen and delta aminolevulinic acid in the urine. The urine 
turns dark when standing due to formation of porphobilin. Treatment 
involves intravenous glucose and intravenous hematin. Other aspects of 
treatment of respiratory support, use of beta blocking agent if tachycardia 
and hypertension are severe and intravenous glucose suppress the heme 
biosynthetic pathway and pyridoxine is also helpful. Prevention is the 
most important strategy before the attack can be precipitated.  
 
VASCULITIC POLYNEUROPATHIES 
Associated with systemic lupus erythematosus, polyarteritis nodosa 
and related disorders develop rapidly and is difficult to differentiating is 
helpful to differentiate between the two disorders from GBS
101
. Careful 
clinical and electrophysiological testing is needed to differentiate 
between the two. In one study three patients with polyarteritis nodosa and 
one with Churg-Strauss became completely paralysed within a week and 
one died of intestinal perforation. However most cases evolve rapidly and 
are usually asymmetrical and multifocal distribution. Even few patients 
with alcoholism, occult carcinoma, Hodgkin disease or renal 
transplantation who developed an acute polyneuropathy as rapid in its 
evolution as GBS has also been described in Refsum disease.  
  
 
 
 
 
 
 
 
TREATMENT OF GBS 
GENERAL MEDICAL ASPECTS 
Respiratory assistance and careful nursing form the corner stone of 
the treatment as the disease remits naturally and the outlook looks 
favorable in most of the cases
98
. About one quarter of the patients 
requires mechanical ventilation in recent era. As the patient’s condition 
fluctuated widely and unpredictably and more over rapidly in the first 
few days of the illness virtually all cases should be admitted in the 
hospital for close monitory of respiratory, autonomic and motor 
dysfunction. 
Maximal respiratory force and expiratory vital capacity is enough 
for the bedside assessment of diaphragmatic strength and respiratory 
function. These measurements help to assess the likelihood of respiratory 
failure. The strength of the neck muscles and trapezii which share the 
same segmental innervation as the diaphragm helps to assess the 
diaphragm function. Single breath count can be used to assess the 
respiratory function. The ability to reach 20 generally corresponds to a 
vital capacity of greater than 1.5 L. If a downward trend in these 
measurements is observed then endotracheal intubation and mechanical 
ventilation should be considered. Incipient respiratory failure should be 
suspected even when there is minor degree of tachypnea and when the 
partial pressure of PaO2 falls below 85 reflecting pulmonary atelectasis. 
Those patients with oropharyngeal weakness required endotracheal 
intubation as early as possible but mechanical ventilation is not always 
required in these kind of cases. These treatments are so demanding that 
these kind of patients should be admitted in intensive care units with 
extensive monitoring by the personal skilled physicians
99
. 
The other major aspects of the treatment in severely debilitated 
patients are the management of cardiac autonomic instability and 
prevention of the medical problems that arise in the critically ill patients. 
Hypotension can occur in 10 percent of the patients and is treated with 
vasopressor and intravenous fluid infusion for a short period of time. 
Hypertension is usually managed with short acting beta blockers like 
labetalol, but care should be taken since precipitous fall in blood pressure 
can be dangerous enough. 
Prevention of electrolyte imbalance, gastrointestinal hemorrhage 
and pulmonary embolism in patients who are bedbound by the use of 
subcutaneous heparin or pneumatic compression boots require careful 
monitoring. Adynamic ileus is a problem which can occur and can even 
lead to perforation in few cases. 
Hyponatremia is another common entitity encountered and is 
usually due to SIADH, and the drop in serum sodium can be produces or 
exaggerated by positive pressure mechanical ventilation. Fluid restriction 
in the case of SIADH or salt supplemention in the case of sodium loss.  
Waking dreams or hallucinations can occur after weeks of 
immobilization. 
Failure to effectively clear the tracheobronchial secretions and the 
need for prolonged ventilation are the usual indications for tracheostomy. 
In most cases this can be postponed until the third week of intubation. 
However rapidly quadriplegic patients and ventilator dependent patients 
may require tracheostomy earlier. Once tracheostomy is performed care 
should be given for adequate tracheal toileting and pulmonary and 
urinary tract infections with adequate antibiotics
101
. 
The decisions to wean and discontinue respiratory aid are based on 
the degree and timing of recovery of respiratory function. The weaning 
process generally begins when the vital capacity reaches 10 ml/kg or 
when comfortable breathing is sustained for a few minutes. Physiotherapy 
should be done to prevent pressure palsies and pressure sores.  
PLASMA EXCHANGE AND IMMUNOGLOBULIN 
The specific treatment includes plasma exchange and intravenous 
immunoglobulin. (IVIG)
 101-104
. If the patient becomes unable to walk 
unaided or if he shows a significant reduction in vital capacity or severe 
oropharyngeal weakness plasmapharesis or IVIG
105
 is instituted as 
promptly as possible. Three large randomized trials comprising more than 
500 patients have established the usefulness of plasma exchange 
administered during the evolving phase of GBS. In the patients who are 
treated within 2 weeks of the onset of symptoms, the hospitalization time 
is halved, mechanical ventilation time is also halved and is the time 
required to achieve ambulation
104
. However if the plasma exchange is 
delayed more than two weeks then the procedure is of little value. 
However if the patient still continues to proceed in the third or fourth 
week of illness then the treatment can be instituted. Young patients 
respond well to plasmapharesis and the preserved compound muscle 
action potential have better prognosis than decreased CMAP. The advised 
regimen is to remove 200-250 ml/kg of plasma in 4-6 treatments on 
alternative days or even in shorter days if there is no 
coagulopathy106
. 
The replacement fluid is saline combined with 5% albumin. The 
need for larger bore needle usually necessitates the implantation of a 
double lumen subclavian or internal jugular catheters and this may lead to 
complications such as pneumothorax, infection and hemorrhage. In some 
cases the treatment can be completed with the antecubital vein. 
Hypotension, hypoprothrombinemia and cardiac arrhythmias can occur as 
complication to plasma exchange. Hepatitis and HIV can be avoided if 
the plasma is replaced with albumin and normal saline rather with pooled 
plasma. 
IVIG is also effective with the dosage of 0.4g/kg per day for 5 
consecutive days and is both easier and safer. In one large study plasma 
exchange was compared with IVIG and there was better result in patients 
treated with plasma exchange but the difference failed to reach any 
statistical significance. Renal failure, proteinuria and aseptic meningitis 
manifested by headache are the complication of IVIG. The gamma 
globulin can cause anaphylaxis and deep venous thrombosis. 
5-10 percent of the patients treated with either plasmapharesis or 
IVIG enter into relapse and becomes apparent several days to 3 weeks 
after treatment. If there was good response to initial therapy then the 
same treatment can be given for the successive relapse. The clinical 
response that occurs in patients treated with IVIG or PE cannot be readily 
discerned in an individual patient.  
The value of corticosteroids alone in the treatment of GBS has been 
disputed. However none of the randomized controlled studies have shown 
the beneficial effect of corticosteroid. Although corticosteroid can no 
longer be recommended as routine treatment for acute GBS few instances 
have shown that intravenous high doses of corticosteroids seemingly 
halted the progress of acute disease
106
. 
PROGNOSIS 
3-5 percent of the patients do not survive the disease even in the 
best of the hospitals. Death is most often due to cardiac arrest, perhaps 
related to dysautonomia, adult respiratory distress syndrome, pneumo or 
hemothorax or accidental machine failure
95
. 
Pulmonary embolism or even sepsis due to prolonged 
immobilization can occur but respiratory failure remains as the main 
cause of death. 
The majority of the patients nearly recover completely with mild 
motor deficits or sensory complaints in the feet or legs. In about 10 
percent of the patients residual disability is more. This occurs in most 
severe and rapidly evolving cased with widespread axonal damage and in 
those requiring prolonged and early ventilation
92
. 
Widespread denervation in EMG associated with decreased 
compound muscle action potential less than 10 percent was associated 
with more severe damage. The average period for ventilator has been 
around 20 days. The older patients recovered more slowly than the 
younger patient. 
The most common residual defects are weakness of the lower leg 
muscles, numbness of toes and feet, and mild facial weakness. Few 
patients had sensory ataxia. Distal neuropathic pain and persistent 
autonomic problems can occur but infrequently. Fatigue, asthenia, muscle 
cramps, dizziness, pain and breathlessness can also occur. Depression is 
an important associated symptom
98
. 
The speed of recovery varies but the pace is steady and can occur 
within a few weeks to months. If the axons are degenerated it can take up 
to 6-18 months to recover. 
 
5-10 percent of the patients have recurrences. An illness that can 
occur as acute demyelinating polyneuropathy may fail to stabilize and 
continue to progress steadily or even may have incomplete remission and 
can progress to develop chronic inflammatory neuropathy. Many grading 
systems have been developed to study the disability that is associated 
with GBS. The scoring systems which has been used to monitor the 
recovery of the patients is the disability scoring system by Hughes which 
comprises of the following parameters and grading. 
 
 
 
HUGHES DISABILITY SCORING
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MATERIAL AND METHODS 
SETTING: 
This study was conducted at the Institute of Internal Medicine, 
IMCU, Rajiv Gandhi Government General Hospital and Madras Medical 
College. 
ETHICAL COMMITTEE APPROVAL: 
Obtained. 
STUDY DURATION: 
This study was conducted over a period of six months.  
STUDY POPULATION: 
Patients admitted with Guillain Barre Syndrome in medical   wards, 
IMCU, Institute of Internal medicine. 
 
 
SAMPLE SIZE: 
Fifty cases of Guillain Barre Syndrome 
TYPE OF STUDY: 
Cross sectional study-Prospective and Retrospective. 
INCLUSION CRITERIA 
 Acute inflammatory demyelinating polyneuropathy.  
EXCLUSION CRITERIA: 
 Hypokalemic periodic paralysis. 
 Diphtheritic paralysis. 
 Traumatic Quadriparesis. 
 Paraneoplastic neuropathy. 
 Vasculitic polyneuropathy. 
 Botulism. 
 Vascular occlusion of spinal artery. 
 Degenerative quadriparesis. 
 Acute transverse myelitis 
 Infectious paraspinal abscess and fractures. 
 Acute disseminated encephalomyelitis.  
 Porphyria induced polyneuropathy.  
DATA COLLECTION AND METHODS 
Informed consent was obtained from each patient or the relative.  
Patients had their history taken according to a Questionnaire and 
were subjected to clinical examination. 
Patients were subjected to routine blood investigations [renal 
function tests (including electrolytes), liver function tests], 
Electrocardiography, complete blood count, chest xray, HIV and HbsAg 
ELISA. 
Cerebrospinal fluid analysis done including CSF sugar, protein, 
LDH, cell count, cytology and cultures.  
Nerve conduction study analysis was done and the conduction 
velocity, latency, blocks, F waves, compound muscle act ion potentials 
were calculated.Patients were classified based on their disability at 15 
days and at discharge using Hughes Disability scoring  scale.  
Various parameters like age, sex, month of admission, preceding 
events, predominant symptoms, cranial nerve involvement, 
dysautonomia, requirement of mechanical ventilation,  electrodiagnostic 
patterns, decreased Compound muscle action potential less than 10 
percent, CSF proteins, presence of albuminocytological dissociation , 
disability grading was done and was correlated with outcome of the 
disease depending on whether there is complete recovery of the disease , 
residual deficit or death. 
All the data were entered in the proforma (enclosed)Data were 
analyzed using SPSS package and ANOVA. 
OBSERVATION AND RESULTS 
TABLE 1 AGE DISTRIBUTION 
 Frequency Percent 
Valid 21-30 19 38.0 
  31-40 14 28.0 
  41-50 10 20.0 
  51-60 4 8.0 
  61-70 3 6.0 
  Total 50 100.0 
TABLE-2 SEX DISTRIBUTION 
 Frequency Percent 
Valid Male 33 66.0 
  Female 17 34.0 
  Total 50 100.0 
TABLE-3 ADMISSION MONTH 
 
 Frequency Percent 
Valid June 14 28.0 
  July 18 36.0 
  August 15 30.0 
  Septem
ber 
3 6.0 
  Total 50 100.0 
    
TABLE-4 PROCEEDING EVENT 
 Frequency Percent 
Valid RTI 12 24.0 
  Age 10 20.0 
  No 28 56.0 
  Total 50 100.0 
TABLE-6 PRESENTING SYMPTOM 
 Frequency Percent 
Valid LL weakness 30 60.0 
  Sensory 
symptoms 
15 30.0 
  UL weakness 5 10.0 
  Total 50 100.0 
 
 
 
 
 
TABLE-7 SENSORY SYMPTOM 
 Frequency Percent 
Valid LL weakness 30 60.0 
  Sensory 
symptoms 
15 30.0 
  UL weakness 5 10.0 
  Total 
50 100.0 
TABLE-8 CRANIAL NERVE INVOLVEMENT 
 
 Frequency Percent 
Valid Yes 21 42.0 
  No 29 58.0 
  Total 50 100.0 
 
TABLE-9 DYSAUTONOMIA 
 
 Frequency Percent 
Valid Yes 18 36.0 
  No 32 64.0 
  Total 50 100.0 
TABLE-10 MECHANICAL VENTILATION 
 Frequency Percent 
Valid Yes 12 24.0 
  No 38 76.0 
  Total 50 100.0 
    
TABLE-11 ALBUMINOCYTOLOGICAL DISSOCIATION 
 
 Frequency Percent 
Valid Yes 39 78.0 
  No 11 22.0 
  Total 50 100.0 
TABLE-12 ELECTRODIAGNOSTIC VARIANT 
 Frequency Percent 
Valid Normal 5 10.0 
  Demyelinative 30 60.0 
  AMAN 10 20.0 
  AMSAN 
 
5 10.0 
  Total 50 100.0 
TABLE-13 DECREASED CMAP<10% OF LOWERLIMIT 
 Frequency Percent 
Valid Yes 9 18.0 
  No 41 82.0 
  Total 50 100.0 
TABLE-14 TREATMENT GIVEN 
 Frequency Percent 
Valid Plasmapharesis 19 38.0 
  IVIg 31 62.0 
  Total 50 100.0 
TABLE-15 AVERAGE LATENCY TO START TREATMENT 
 Frequency Percent 
Valid 3 33 66.0 
  4 16 32.0 
  5 1 2.0 
  Total 50 100.0 
    
 
 
 
TABLE-16 OUTCOME 
 
 Frequency Percent 
Valid 3 33 66.0 
  4 16 32.0 
  5 1 2.0 
  Total 50 100.0 
    
TABLE-17 HUGHES DISABILITY SCORING AT 15 DAYS 
 FREQUENCY 
 
 
PERCENT 
VALID  
GRADE 0 
 
GRADE 1 
 
 
GRADE 2 
 
- 
 
- 
 
4 
- 
 
- 
 
8.0 
  GRADE 3 23 46.0 
  GRADE 4 11 22.0 
  GRADE 5 12 24.0 
  TOTAL 
50 100.0 
 
 
AT DISCHARGE/DEATH 
  Frequency Percent 
Valid Grade 0 29 58.0 
  Grade 1 5 10.0 
  Grade 2 6 12.0 
  Grade 3 5 10.0 
  Grade 5 5 10.0 
  Total 50 100.0 
 
TABLE-18 RECOVERY 
 
 Frequency Percent 
Valid Complete Recovery 27 54.0 
  Residual Deficit 17 34.0 
  Total 45 90.0 
Total 50 100.0 
 
 
 
 
 
COMPARISON BETWEEN THE ABOVE PARAMETERS AND OUTCOME OF 
THE DISEASE 
TABLE-19 AGE DISTRIBUTION AND OUTCOME(DEATH) 
    Outcome 
Total 
  
19 
P value 
    Death Survive  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0.454 
Age in 
years 
21-30 Count 
2 17 
    % within 
Age in 
years 
10.5% 89.5% 100.0% 
    % within 
Outcome 
40.0% 37.8% 38.0% 
  31-40 Count 2 12 14 
    % within 
Age in 
years 
14.3% 85.7% 100.0% 
    % within 
Outcome 
40.0% 26.7% 28.0% 
  41-50 Count 0 10 10 
    % within 
Age in 
years 
.0% 100.0% 100.0% 
    % within 
Outcome 
.0% 22.2% 20.0% 
  51-60 Count 0 4 4 
    % within 
Age in 
years 
.0% 100.0% 100.0% 
    % within 
Outcome 
.0% 8.9% 8.0% 
  61-70 Count 1 2 3 
    % within 
Age in 
years 
33.3% 66.7% 100.0% 
    % within 
Outcome 
20.0% 4.4% 6.0% 
Total Count 5 45 50 
  % within 
Age in 
years 
10.0% 90.0% 100.0% 
  % within 
Outcome 
100.0% 100.0% 100.0% 
  
In our study group, the relationship between age and outcome (death) is 
insignificant with the p value of 0.454 
 
 
 
TABLE-20 SEX DISTRIBUTION AND MORTALITY 
Age in years
61-7051-6041-5031-4021-30
C
o
u
n
t
20
10
0
Outocme
Death
Survive
   Outcome Total P value 
 
 
 
 
 
 
 
0.560 
    Death Survive   
Sex Male Count 3 30 33 
    % within 
Sex 
9.1% 90.9% 100.0% 
    % within 
Outcome 
60.0% 66.7% 66.0% 
  Female Count 2 15 17 
    % within 
Sex 
11.8% 88.2% 100.0% 
    % within 
Outcome 
40.0% 33.3% 34.0% 
Total Count 5 45 50 
  % within 
Sex 
10.0% 90.0% 100.0% 
  % within 
Outcome 
100.0% 100.0% 100.0% 
 
 
 
 The relationship between sex and outcome (death) is  insignificant with 
the p value of  0.564 
 
 
 
 
TABLE-21 ADMISSION MONTH AND MORTALITY 
Sex
FemaleMale
C
o
u
n
t
40
30
20
10
0
Outocme
Death
Survive
   Outcome Total P value 
    Death Survive   
Admission 
Month 
June Count 
1 13 14 
 
    % within 
Admission 
Month 
7.1% 92.9% 100.0% 
 
    % within 
Outcome 
20.0% 28.9% 28.0% 
 
  July Count 0 18 18  
    % within 
Admission 
Month 
.0% 100.0% 100.0% 
 
    % within 
Outcome 
.0% 40.0% 36.0% 
0.069 
  August Count 4 11 15  
    % within 
Admission 
Month 
26.7% 73.3% 100.0% 
 
    % within 
Outcome 
80.0% 24.4% 30.0% 
 
  September Count 0 3 3  
    % within 
Admission 
Month 
.0% 100.0% 100.0% 
 
    % within 
Outcome 
.0% 6.7% 6.0% 
 
Total Count 5 45 50  
  % within 
Admission 
Month 
10.0% 90.0% 100.0% 
 
  % within 
Outcome 
100.0% 100.0% 100.0% 
 
 
 
  
Admission month had no significance on the mortality of the 
patients p value=0.069 
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TABLE 22-PRECEDING EVENT AND MORTALITY 
   Outcome Total P value 
    Death Survive   
Preceding 
Event 
RTI Count 
4 8 12 
 
    % within 
Preceding 
Event 
33.3% 66.7% 100.0% 
 
    % within 
outcome 
80.0% 17.8% 24.0% 
0.006 
  AGE Count 1 9 10  
    % within 
Preceding 
Event 
10.0% 90.0% 100.0% 
 
    % within 
outcome 
20.0% 20.0% 20.0% 
 
  No Count 0 28 28  
    % within 
Preceding 
Event 
.0% 100.0% 100.0% 
 
    % within 
outcome 
.0% 62.2% 56.0% 
 
Total Count 5 45 50  
  % within 
Preceding 
Event 
10.0% 90.0% 100.0% 
 
  % within 
Outcome 
100.0% 100.0% 100.0% 
 
 
TABLE-23 PRESENTING SYMPTOM AND MORTALITY 
   Outcome Total P value 
    Death Survive   
Presenting 
Symptom 
LL weakness Count 
5 25 30 
 
    % within 
Presenting 
Symptom 
16.7% 83.3% 100.0% 
 
    % within 
outcome 
100.0% 55.6% 60.0% 
 
  Sensory 
symptoms 
Count 
0 15 15 
0.157 
    % within 
Presenting 
Symptom 
.0% 100.0% 100.0% 
 
    % within 
outcome 
.0% 33.3% 30.0% 
 
  UL weakness Count 0 5 5  
    % within 
Presenting 
Symptom 
.0% 100.0% 100.0% 
 
    % within 
outcome 
.0% 11.1% 10.0% 
 
Total Count 5 45 50  
  % within 
Presenting 
Symptom 
10.0% 90.0% 100.0% 
 
  % within 
outcome 
100.0% 100.0% 100.0% 
 
 
P value =0.157 
 
 
TABLE-25 CRANIAL NERVE INVOLVEMENT AND MORTALITY 
   outcome Total P value 
 
 
 
 
 
 
 
 
 
 
0.010 
    Death Survive   
Cranial 
Nerve 
Involvem
ent 
Yes Count 
5 16 21 
    % within 
Cranial 
Nerve 
Involvem
ent 
23.8% 76.2% 100.0% 
    % within 
outcome 
100.0% 35.6% 42.0% 
  No Count 0 29 29 
    % within 
Cranial 
Nerve 
Involvem
ent 
.0% 100.0% 100.0% 
    % within 
outcome 
.0% 64.4% 58.0% 
Total Count 5 45 50 
  % within 
Cranial 
Nerve 
Involvem
ent 
10.0% 90.0% 100.0% 
  % within  100.0% 100.0% 100.0% 
 
 
 
 Cranial nerve involvement was found to have significant relationship 
with outcome- death of the patient. p value 0.010- highly significant 
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TABLE-26 DYSAUTONOMIA AND MORTALITY 
   Outcome Total P value 
 
 
 
 
 
 
 
 
0.004 
    Death Survive   
Dysautonomia Yes Count 5 13 18 
    % within 
Dysautonomia 
27.8% 72.2% 100.0% 
    % within 
Outcome 
100.0% 28.9% 36.0% 
  No Count 0 32 32 
    % within 
Dysautonomia 
.0% 100.0% 100.0% 
    % within 
Outcome 
.0% 71.1% 64.0% 
Total Count 5 45 50 
  % within 
Dysautonomia 
10.0% 90.0% 100.0% 
  % within 
Outcome 
100.0% 100.0% 100.0% 
 
 Dysautonomia and mortality had strong correlation with the p 
value=0.004 
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TABLE-27 MECHANICAL VENTILATION AND MORTALITY 
   Outcome Total P value 
 
 
 
 
 
 
 
0.000 
    Death Survive   
Mechanical 
Ventilation 
Yes Count 
5 7 12 
    % within Mechanical 
Ventilation 
41.7% 58.3% 100.0% 
    % within outcome 100.0% 15.6% 24.0% 
  No Count 0 38 38 
    % within Mechanical 
Ventilation 
.0% 100.0% 100.0% 
    % within Outcome .0% 84.4% 76.0% 
Total Count 5 45 50 
  % within Mechanical 
Ventilation 
10.0% 90.0% 100.0% 
  % within Outcome 100.0% 100.0% 100.0% 
  
Mechanical ventilation had a very high significance with the mortality of 
the disease with p value being highly significant of <0.001. 
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TABLE 30-ELECTRODIAGNOSTIC VARIANT AND MORTALITY 
   Outocme Total P value 
 
 
 
 
 
 
 
 
 
 
0.000 
    Death Survive   
Electro 
diagnostic 
Variant 
Normal Count 
0 5 5 
    % within 
Electrodiagnostic 
Variant 
.0% 100.0% 100.0% 
    % within 
Outcome 
.0% 11.1% 10.0% 
  Demyelinative Count 0 30 30 
    % within Electro 
diagnostic 
Variant 
.0% 100.0% 100.0% 
    % within 
Outcome 
.0% 66.7% 60.0% 
  AMAN Count 5 5 10 
    % within 
Electrodiagnostic 
Variant 
50.0% 50.0% 100.0% 
    % within 
Outcome 
100.0% 11.1% 20.0% 
  AMSAN Count 0 5 5 
    % within 
Electrodiagnostic 
Variant 
.0% 100.0% 100.0% 
    % within 
Outcome 
.0% 11.1% 10.0% 
Total Count 5 45 50 
  % within 
Electrodiagnostic 
Variant 
10.0% 90.0% 100.0% 
  % within 
Outcome 
100.0% 100.0% 100.0% 
 
 The electrodiagnostic variants of AMAN and AMSAN had 
significant relationship with outcome p value=<0.001. 
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TABLE-31 DECREASED CMAP<10% LOWERLIMIT AND 
MORTALITY 
   Outcome Total P value 
 
 
 
 
 
 
 
0.000 
    Death Survive   
Decreased 
CMAP<10% 
of Lowerlimit 
Yes Count 
5 4 9 
    % within 
Decreased 
CMAP<10% 
of Lowerlimit 
55.6% 44.4% 100.0% 
    % within 
Outcome 
100.0% 8.9% 18.0% 
  No Count 0 41 41 
    % within 
Decreased 
CMAP <10% 
of Lowerlimit 
.0% 100.0% 100.0% 
    % within 
Outcome 
.0% 91.1% 82.0% 
Total Count 5 45 50 
  % within 
Decreased 
CMAP <10% 
of Lowerlimit 
10.0% 90.0% 100.0% 
  % within 
Outcome 
100.0% 100.0% 100.0% 
 
Decreased CMAP of <10% of lower limit had significant correlation with 
outcome with p value=<0.001 
 
 
TABLE-32 TREATMENT AND MORTALITY 
   Death Survive   P value 
Treatment 
given 
Plasmapharesis Count 
5 14 19 
 
    % within 
Treatment 
given 
26.3% 73.7% 100.0% 
 
    % within 
Outocme 
100.0% 31.1% 38.0% 
 
  IVIg Count 0 31 31  
    % within 
Treatment 
given 
.0% 100.0% 100.0% 
0.003 
    % within 
Outocme 
.0% 68.9% 62.0% 
 
Total Count 5 45 50  
  % within 
Treatment 
given 
10.0% 90.0% 100.0% 
 
  % within 
Outocme 
100.0% 100.0% 100.0% 
 
P value 0.003 
 
 
TABLE-34 HUGHES DISABILITY SCORE AT 15 DAYS AND 
MORTALITY 
   Outcome Total P value 
    Death Survive    
Hughes 
Disabilty 
Grading Score 
at 15 Days 
Grade 2 Count 
0 4 4 
 
    % within 
Hughes 
Disability 
Grading Score 
at 15 Days 
.0% 100.0% 100.0% 
 
    % within 
Outcome 
.0% 8.9% 8.0% 
 
  Grade 3 Count 0 23 23  
    % within 
Hughes 
Disability 
Grading Score 
at 15 Days 
.0% 100.0% 100.0% 
 
    % within 
Outcome 
.0% 51.1% 46.0% 
 
  Grade 4 Count 0 11 11  
    % within 
Hughes 
Disability 
Grading Score 
at 15 Days 
.0% 100.0% 100.0% 
0.001 
    % within 
Outcome 
.0% 24.4% 22.0% 
 
  Grade 5 Count 5 7 12  
    % within 
Hughes 
Disability 
Grading Score 
at 15 Days 
41.7% 58.3% 100.0% 
 
    % within 
Outcome 
100.0% 15.6% 24.0% 
 
Total Count 5 45 50  
  % within 
Hughes 
Disability 
Grading Score 
at 15 Days 
10.0% 90.0% 100.0% 
 
  % within 
Outcome 
100.0% 100.0% 100.0% 
 
P value significant<0.001 
TABLE-35 HUGHES DISABILITY SCORING AT 
DISCHARGE/DEATH 
   Outcome Total  
    Death Survive   P value 
At discharge/ 
death 
Grade 0 Count 
0 29 29 
 
    % within At 
Discharge 
/Death 
.0% 100.0% 100.0% 
 
    % within 
Outcome 
.0% 64.4% 58.0% 
 
  Grade 1 Count 0 5 5  
    % within At 
Discharge 
/Death 
.0% 100.0% 100.0% 
 
    % within 
Outcome 
.0% 11.1% 10.0% 
 
  Grade 2 Count 0 6 6  
    % within At 
Discharge 
Death 
.0% 100.0% 100.0% 
 
    % within 
Outcome 
.0% 13.3% 12.0% 
 
  Grade 3 Count 0 5 5 0.000 
    % within At 
Discharge 
/Death 
.0% 100.0% 100.0% 
 
    % within 
Outcome 
.0% 11.1% 10.0% 
 
  Grade 5 Count 5 0 5  
    % within At 
Discharge 
/Death 
100.0% .0% 100.0% 
 
    % within 
Outcome 
100.0% .0% 10.0% 
 
Total Count 5 45 50  
  % within At 
Discharge 
 
 
10.0% 90.0% 100.0% 
 
  % within 
Outcome 
100.0% 100.0% 100.0% 
 
P value is significant <0.001 
TABLE-36- AGE DISTRIBUTION AND RECOVERY/DISABILITY 
    Recovery Total 
P value 
    
Complete 
Recovery 
Residual 
Deficit   
 
Age in 
years 
21-30 Count 
9 8 17 
 
    % within 
Age in 
years 
52.9% 47.1% 100.0% 
 
    % within 
Recovery 
32.1% 47.1% 37.8% 
 
  31-40 Count 7 5 12  
    % within 
Age in 
years 
58.3% 41.7% 100.0% 
 
    % within 
Recovery 
25.0% 29.4% 26.7% 
 
  41-50 Count 8 2 10  
    % within 
Age in 
years 
80.0% 20.0% 100.0% 
 
    % within 
Recovery 
28.6% 11.8% 22.2% 
0.476 
  51-60 Count 2 2 4  
    % within 
Age in 
years 
50.0% 50.0% 100.0% 
 
    % within 
Recovery 
7.1% 11.8% 8.9% 
 
  61-70 Count 2 0 2  
    % within 
Age in 
years 
100.0% .0% 100.0% 
 
    % within 
Recovery 
7.1% .0% 4.4% 
 
Total Count 28 17 45  
  % within 
Age in 
years 
62.2% 37.8% 100.0% 
 
  % within 
Recovery 
100.0% 100.0% 100.0% 
 
 
Age had no significance with degree of recovery p value=0.476 
 
TABLE-37 SEX DISTRIBUTION AND RECOVERY/DISABILITY 
    Recovery Total 
 
    
Complete 
Recovery 
Residual 
Deficit   
P value 
Sex Male Count 22 8 30  
    % within 
Sex 
73.3% 26.7% 100.0% 
 
    % within 
Recovery 
78.6% 47.1% 66.7% 
 
  Female Count 6 9 15  
    % within 
Sex 
40.0% 60.0% 100.0% 
0.033 
    % within 
Recovery 
21.4% 52.9% 33.3% 
 
Total Count 28 17 45  
  % within 
Sex 
62.2% 37.8% 100.0% 
 
  % within 
Recovery 
100.0% 100.0% 100.0% 
 
 
 Sex and degree of recovery had grade 2 degree of significance with  
p value=0.033 
 
 
 
 
 
 
 
 
 
TABLE-38 ADMISSION MONTH AND RECOVERY/DISABILITY 
     Recovery Total 
 
    
Complete 
Recovery 
Residual 
Deficit   
P value 
Admission 
Month 
June Count 
8 5 13 
 
    % within 
Admission 
Month 
61.5% 38.5% 100.0% 
 
    % within 
Recovery 
28.6% 29.4% 28.9% 
 
  July Count 11 7 18  
    % within 
Admission 
Month 
61.1% 38.9% 100.0% 
 
    % within 
Recovery 
39.3% 41.2% 40.0% 
 
  August Count 8 3 11  
    % within 
Admission 
Month 
72.7% 27.3% 100.0% 
0.661 
    % within 
Recovery 
28.6% 17.6% 24.4% 
 
  September Count 1 2 3  
    % within 
Admission 
Month 
33.3% 66.7% 100.0% 
 
    % within 
Recovery 
3.6% 11.8% 6.7% 
 
Total Count 28 17 45  
  % within 
Admission 
Month 
62.2% 37.8% 100.0% 
 
  % within 
Recovery 
100.0% 100.0% 100.0% 
 
 
Admission month had no significance with degree or recovery 
 p value=0.661 
 
TABLE 39-PRECEDING EVENT AND RECOVERY/DISABILITY 
    Recovery Total 
 
    
Complete 
Recovery 
Residual 
Deficit   
P value 
Preceding 
Event 
RTI Count 
3 5 8 
 
    % within 
Preceding 
Event 
37.5% 62.5% 100.0% 
 
    % within 
Recovery 
10.7% 29.4% 17.8% 
 
  Age Count 5 4 9  
    % within 
Preceding 
Event 
55.6% 44.4% 100.0% 
 
    % within 
Recovery 
17.9% 23.5% 20.0% 
0.196 
  No Count 20 8 28  
    % within 
Preceding 
Event 
71.4% 28.6% 100.0% 
 
    % within 
Recovery 
71.4% 47.1% 62.2% 
 
Total Count 28 17 45  
  % within 
Preceding 
Event 
62.2% 37.8% 100.0% 
 
  % within 
Recovery 
100.0% 100.0% 100.0% 
 
 
            Preceding event had no significance with degree of recovery with 
 p value =0.196 
 
 
 
TABLE-40 PRESENTING SYMPTOM AND 
RECOVERY/DISABILITY 
    Recovery Total 
 
    
Complete 
Recovery 
Residual 
Deficit   
P value 
Presenting 
Symptom 
LL weakness Count 
18 7 25 
 
    % within 
Presenting 
Symptom 
72.0% 28.0% 100.0% 
 
    % within 
Recovery 
64.3% 41.2% 55.6% 
 
  Sensory 
symptoms 
Count 
6 9 15 
 
    % within 
Presenting 
Symptom 
40.0% 60.0% 100.0% 
0.089 
    % within 
Recovery 
21.4% 52.9% 33.3% 
 
  UL weakness Count 4 1 5  
    % within 
Presenting 
Symptom 
80.0% 20.0% 100.0% 
 
    % within 
Recovery 
14.3% 5.9% 11.1% 
 
Total Count 28 17 45  
  % within 
Presenting 
Symptom 
62.2% 37.8% 100.0% 
 
  % within 
Recovery 
100.0% 100.0% 100.0% 
 
 
*LL-LOWERLIMB UL-UPPERLIMB 
Preceding symptom had no significance with degree of recovery with 
 p value=0.089 
 
 
TABLE- 41CRANIAL NERVE INVOLVEMENT AND 
RECOVERY/DISABILITY 
    Recovery Total 
P value 
    
Complete 
Recovery 
Residual 
Deficit   
 
Cranial 
Nerve 
Involvement 
Yes Count 
2 14 16 
 
    % within 
Cranial 
Nerve 
Involvemen
t 
12.5% 87.5% 100.0% 
 
    % within 
Recovery 
7.1% 82.4% 35.6% 
 
  No Count 26 3 29  
    % within 
Cranial 
Nerve 
Involvemen
t 
89.7% 10.3% 100.0% 
 
    % within 
Recovery 
92.9% 17.6% 64.4% 
0.000 
Total Count 28 17 45  
  % within 
Cranial 
Nerve 
Involvemen
t 
62.2% 37.8% 100.0% 
 
  % within 
Recovery 
100.0% 100.0% 100.0% 
 
 
Cranial nerve involvement has higher significance with pattern of   recovery 
with p value of <0.001 
. 
 
 
TABLE-42 DYSAUTONOMIA AND RECOVERY/DISABILITY 
  
    Recovery Total  
    
Complete 
Recovery 
Residual 
Deficit   
P value 
Dysautonomia Yes Count 2 11 13  
    % within 
Dysautonomia 
15.4% 84.6% 100.0% 
 
    % within 
Recovery 
7.1% 64.7% 28.9% 
 
  No Count 26 6 32  
    % within 
Dysautonomia 
81.3% 18.8% 100.0% 
 
    % within 
Recovery 
92.9% 35.3% 71.1% 
<0.001 
Total Count 28 17 45  
  % within 
Dysautonomia 
62.2% 37.8% 100.0% 
 
  % within 
Recovery 
100.0% 100.0% 100.0% 
 
 
 Dysautonomia had grade 1 significance with degree of recovery with  
  p value of <0.001 
 
 
 
 
TABLE-43 MECHANICAL VENTILATION AND 
RECOVERY/DISABILITY 
    Recovery Total 
 
    
Complete 
Recovery 
Residual 
Deficit   
P value 
Mechanical 
Ventilation 
Yes Count 
0 7 7 
 
    % within 
Mechanical 
Ventilation 
.0% 100.0% 100.0% 
 
    % within 
Recovery 
.0% 41.2% 15.6% 
 
  No Count 28 10 38  
    % within 
Mechanical 
Ventilation 
73.7% 26.3% 100.0% 
<0.001 
    % within 
Recovery 
100.0% 58.8% 84.4% 
 
Total Count 28 17 45  
  % within 
Mechanical 
Ventilation 
62.2% 37.8% 100.0% 
 
  % within 
Recovery 
100.0% 100.0% 100.0% 
 
  
Requirement of mechanical ventilation had significant correlation with recovery 
with p value=<0.001 
 
 
 
 
 
TABLE-45 ELECTRODIAGNOSTIC VARIANT AND 
RECOVERY/DISABILITY 
   Recovery Total 
 
   
Complete 
Recovery 
Residual 
Deficit  
P 
value 
Electrodiagnostic 
Variant 
Normal Count 
4 1 5 
 
    % within 
Electrodiagnostic 
Variant 
80.0% 20.0% 100.0% 
 
    % within Recovery 14.3% 5.9% 11.1%  
  Demyelinative Count 23 7 30  
    % within 
Electrodiagnostic 
Variant 
76.7% 23.3% 100.0% 
 
    % within Recovery 82.1% 41.2% 66.7%  
  Aman Count 0 5 5 0.002 
    % within 
Electrodiagnostic 
Variant 
.0% 100.0% 100.0% 
 
    % within Recovery .0% 29.4% 11.1%  
  Amsan Count 1 4 5  
    % within 
Electrodiagnostic 
Variant 
20.0% 80.0% 100.0% 
 
    % within Recovery 3.6% 23.5% 11.1%  
Total Count 28 17 45  
  % within 
Electrodiagnostic 
Variant 
62.2% 37.8% 100.0% 
 
  % within Recovery 100.0% 100.0% 100.0%  
Electrodiagnostic  pattern with axonal variant had significant correlation with 
recovery with  p value =0.002 
 
TABLE-46 DECREASED CMAP<10% OF LOWERLIMIT AND 
RECOVERY/DEATH 
    Recovery Total  
    
Complete 
Recovery 
Residual 
Deficit   
P value 
Decreased 
CMAP<10% 
of lower limit 
Yes Count 
0 4 4 
 
    % within 
Decreased 
CMAP<10% 
of lower limit 
.0% 100.0% 100.0% 
0.007 
    % within 
Recovery 
.0% 23.5% 8.9% 
 
  No Count 28 13 41  
    % within 
Decreased 
CMAP<10% 
of lower limit 
68.3% 31.7% 100.0% 
 
    % within 
Recovery 
100.0% 76.5% 91.1% 
 
Total Count 28 17 45  
  % within 
Decreased 
CMAP<10% 
of Lower limit 
62.2% 37.8% 100.0% 
 
  % within 
Recovery 
100.0% 100.0% 100.0% 
 
 
Decreased CMAP <10% of lower limit had significant correlation with recovery 
P value=0.007 
 
TABLE-48 HUGHES DISABILITY GRADING SCORE AT 15 DAYS 
AND RECOVERY/DISABILITY 
 
    Recovery Total 
 
    
Complete 
Recovery 
Residual 
Deficit   
P value 
Hughes 
Disabilty 
Grading Score 
at 15 Days 
Grade 2 Count 
4 0 4 
 
    % within 
Hughes 
Disability 
Grading Score 
at 15 Days 
100.0% .0% 100.0% 
 
    % within 
Recovery 
14.3% .0% 8.9% 
 
  Grade 3 Count 19 4 23 <0.001 
    % within 
Hughes 
Disability 
Grading Score 
at 15 Days 
82.6% 17.4% 100.0% 
 
    % within 
Recovery 
67.9% 23.5% 51.1% 
 
  Grade 4 Count 5 6 11  
    % within 
Hughes 
Disability 
Grading Score 
at 15 Days 
45.5% 54.5% 100.0% 
 
    % within 
Recovery 
17.9% 35.3% 24.4% 
 
  Grade 5 Count 0 7 7  
    % within 
Hughes 
Disability 
Grading Score 
at 15 Days 
.0% 100.0% 100.0% 
 
    % within 
Recovery 
.0% 41.2% 15.6% 
 
Total Count 28 17 45  
  % within 
Hughes 
Disability 
Grading Score 
at 15 Days 
62.2% 37.8% 100.0% 
 
  % within 
Recovery 
100.0% 100.0% 100.0% 
 
HUGHES DISABILITY AT DISCHARGE AND 
RECOVERY/DISABILITY 
     Recovery Total 
 
    
Complete 
Recovery 
Residual 
Deficit   
P value 
At 
Discharge/Deat
h 
Grade 0 Count 
28 1 29 
 
    % within At 
Discharge/Death 
96.6% 3.4% 100.0% 
 
    % within 
Recovery 
100.0% 5.9% 64.4% 
 
  Grade 1 Count 0 5 5  
    % within At 
Discharge/Death 
.0% 100.0% 100.0% 
 
    % within 
Recovery 
.0% 29.4% 11.1% 
 
  Grade 2 Count 0 6 6  
    % within At 
Discharge/Death 
.0% 100.0% 100.0% 
<0.001 
    % within 
Recovery 
.0% 35.3% 13.3% 
 
  Grade 3 Count 0 5 5  
    % within At 
Discharge/Death 
.0% 100.0% 100.0% 
 
    % within 
Recovery 
.0% 29.4% 11.1% 
 
Total Count 28 17 45  
  % within At 
Discharge/Death 
62.2% 37.8% 100.0% 
 
  % within 
Recovery 
100.0% 100.0% 100.0% 
 
 
         Hughes disability scoring had significant correlation with recovery at 15 
days and at discharge with p value=<0.001 
 
 
TABLE-49 RESULTS 
The mean age group of our study population was 35.77 years. The respective 
age group related percentages are as follows. 38% of the patients were in the 
age group of 21-30 years, 28% of the patients in the age group of 31-40 years, 
20% in 41-50 years, 8% in 51-60 years, 6% in 61-70 years. 66% of the patients 
were males and 34% of the patients were females.  
GBS cases occurred in maximum number during our study period of July 
comprising 36%, August-30%, June-28%, September-6%. The average duration 
of hospital stay was 21.2 days. 
 22% of the patients had preceding events. RTI was present in 55% of the 
patients and AGE was present in 10% of the patients. 
The presenting symptom was lower limb weakness in 60% of the patients, 
sensory symptoms in 15% of the patients and upper limb weakness in 10% of 
the patients. 42% of the patients had cranial nerve involvement, 36% of the 
patients had dysautonomia and 24% of the patients required mechanical 
ventilation in our study. The average duration of ventilator dependence was 
14.5 days.  
Average CSF protein was 76.03 mg%. Albumino-cytological dissociation was 
present in 78% of the cases.  
Nerve conduction study revealed Demyelinative type in 60% of the patients, 
AMAN variant in 22% of the patients, AMSAN variant in 10% of the patients 
and it was normal in 8% of the patients. Decreased CMAP <10% was taken as a 
component of nerve conduction study as it was found to be a major determinant 
of prognosis in various randomized controlled study and it was found to be 
present in 18% of patients. 
These patients were treated with plasmapharesis in 38% and IVIG was given in 
62% of the patients. The average latency for starting the treatment was 3.36 
days. 5 patients(10%) died in our study group and more than two thirds of the 
patients were associated with dysautonomia and required mechanical 
ventilation. 
The factors affecting the outcome at discharge both morbidity and mortality 
were found to be  
1. Presence of multiple cranial nerve involvement 
2. Requirement of mechanical ventilation. 
3. Presence of dysautonomia 
4. features of axonapathy –AMAN and AMSAN variant in nerve 
conduction study 
 
5. Decreased CMAP<10 percent in nerve conduction study. 
 
TABLE-50   DISCUSSION 
Guillaine barre syndrome is the commonest cause of acute and subacute 
flaccid quadriparesis. Its distribution and occurrence is worldwide and it does 
not have much seasonal variation and it affects both children and the adult 
population with no sex predilection. 
Usually heralded by a preceding event of respiratory or gastrointestinal 
infection or immunization which precedes the disease process by 3 weeks in 
upto 61% of the cases. There are numerous disease association with GBS, 
viruses, bacteria, immunization, trauma, surgery, connective tissue disorders 
and even pregnancy which can be followed by acute inflammatory 
demyelinating polyneuropathy. 
 
In our study group the mean age of the population is 35.77 years. The 
patients in the age group of 20-40 years were maximum comprising of around 
66%. But in large scale prospective study done by the Italian GBS group 
comprising of 297 study population, maximum age group belonged to the older 
population of 55 years comprising of 46.8%. In the indian subcontinent, varies 
GBS study groups conducted at NIMHANS, kerala and other south indian 
counterparts correlated well with our study group with the maximum number of 
patients belonging to the 2
nd
 and 3
rd
 decade of life. As these study groups were 
smaller and due to our small sample size of 50 this age difference might have 
occurred, but the middle aged population is affected more when compared to the 
western population 
The male female ration is 3:2, demonstrated by many large randomized 
controlled trials in our study group the ratio was 2:1 with male population 
comprising of around 66% and the female population is 34%. Hughes et al 
study showed a male: female ratio of 1.5:1. The neurology society of 
Netherland showed the same along with Alshekhelee et al group demonstrated  
2:1 male female ratio 
The age distribution and the sex distribution did not seem to affect the 
outcome of the disease-death or the degree of recovery with the p value being 
greater than 0.05 
 
In our study group the maximum number of cases occurred in the period 
of July followed by June comprising a total of 64% of the cases. Similar results 
were obtained in the GBS study group of China with slight increase during the 
summer. The Ho TW et al group in northern china reported a increased 
incidence of GBS in the summers and it has been associated with 
Campylobacter jejuni and other viral infections. The month of occurrence did 
not have any significance with the recovery or death of the patients. Similar 
pattern was observed by van Koningsweld et al on the Caribbean island during 
the years of 1996 but it has come down back to normal in 2006. 
The most common preceding event in our study group was respiratory 
tract infection comprising of around 24 percent and 10 percent of the cases had 
preceding gastrointestinal infection. Koga M, Yuki et al in Japan observed 
cough (48%) and sore throat (39%) with nasal discharge (30%) and diarrhea 
present in 27% of the patients. The preceding events did not have significance 
on the morbidity but the recovery rate had significance with preceding events. 
The commonest subtype of GBS in our study population was 
demyelinating type comprising 60% with axonal variant comprising 30%. There 
was no Miller fisher variant in our study population and 10% of the patients 
were normal. The Rong kuo Lyo et all study group had 49% of the patients 
which were demyelinative, 4% axonal,19% MFS and 28% were unclassified. 
Hughes et al study population showed a sensory motor form to be the most 
common axonal variant in the European and North American territory. Ho TW 
et al showed an the axonal variants were around 5-10%. Similar results were 
obtained by Mckhann GM et al., and Griffin JW et al., The variants were found 
to affect the recovery and mortality of the patients with poor outcome and 
mortality observed in axonal variants compared to demyelinating variants in our 
study group with the maximum death in the acute motor axonal neuropathy. 
Lower limb weakness was the commonest presenting symptom in 60% of 
the patients, sensory involvement in 30% of the patients and Upper limb 
weakness was noted in 10 percent of the patients. In the Taiwan GBS study 
group by Rong Kuo Lyu et al., 60% has sensory involvement. In the Spanish 
study group by Sedano MJ et al., 66.7% had sensory involvement. The 
presenting symptom did not have any effect on mortality but recovery rate 
seemed to have significance with the presenting symptoms with those involving 
the lower limb and sensory symptoms as the initial symptoms seemed to have 
residual deficit.  
Cranial nerve involvement was present in 42% of the patients in our study 
group and the facial nerve paralysis was the most common observed palsy 
followed by Bulbar palsy and ocular palsy. The Spanish study group had 43.5% 
with cranial nerve involvement; the Taiwan study group had 60% of the study 
population with cranial nerve involvement. Ito M, Kuwabara et al., found that 
facial nerve involvement is the most common present in 70% with Bulbar and 
oculomotor nerves less affected. Bickerstaff brainstem encephalitis was the 
striking feature of the above study group. Cranial nerve involvement seemed 
have significant effect on mortality, ventilator dependence and residual deficits 
were more in our study group. 
 
Dysautonomia was present in 36% of the patients in our study population 
and it was directly related to ventilator dependence and mortality in our study 
group. It occurred in less than two third of the patients in our study population 
and this may be due to the smaller size of our study population. Singh NK et al., 
Moulin et al and Winer JB showed that arrhythmias are more prevalent in the 
group with Dysautonomia. Sinus tachycardia was the most common 
Dysautonomic feature in our study with fluctuating blood pressure. 
Dysautonomia was the major cause of mortality in our study group. 
Mechanical ventilation was required in 24% of the patients in our study 
group. The average duration of ventilator dependence was 14.5 days in our 
study group. The Rong Kyo Lyu et al., study group had 20.9% with ventilator 
dependence. 10 days was the average duration on ventilator. J.H. Rees et al., 
study group showed 25% of the patient’s required mechanical ventilation, the 
study was conducted in South East England with average duration of 42 days. 
Mechanical ventilation was directly related to mortality and poor recover in our 
study population. 
 
Nerve conduction study was done and Decreased compound muscle 
action potential was observed. Decreased CMAP <10 percent was present in 18 
percentage of the patients. It had higher significance with morbidity and 
mortality with P value of <0.001 . Similar results were obtained by the Spanish 
GBS group by Sedona MJ et al., and Taiwan group by Rong Kuo Lyo et al., 
Decreased CMAP is a significant electrodiagnostic finding which has greater 
significance with recovery and mortality. 
 
Albuminocytological dissociation was present in 78 percent of the 
patients and it had no significance with morbidity or mortality of the patients in 
our study group. The disability was calculated using Hughes disability score and 
it had greater value in the predictability of morbidity and mortality in our study 
group. It is a simple bedside analytical score comprising of 6 scores. Grade 0 is 
without symptoms, grade 6 being death. Grade 1 and 2 with mild symptoms, 
Grade 3 , 4 and 5 with progressive worsening of symptoms culminating in 
respiratory failure, moribund status and ventilator dependence. It was a reliable 
and quick bed side analytical index of prognosis observed by Hughes et al study 
group. 
The patients were treated with plasmpharesis 19% and IVIG was given in 
62% of the patients. In our study group the patients with severe debilitating 
symptoms were started directly on plasmapharesis in comparison to the IVIG 
treated groups, hence mortality was found to be slighter higher in the 
plasmapharesis treated group. Van der Meche et al., Hughes et al., and Plasma 
exchange /Sandoglobulin Guillain-Barre Syndrome trial found no difference in 
the efficacy of plasmapharesis to IVIG and combination of both were not found 
to be helpful or better over the other. 
LIMITATION OF THE STUDY 
Small study group 
Absence of follow up study 
 
 
TABLE-51 CONCLUSION 
Guillaine Barre syndrome is the commonest cause of acute flaccid 
quadriparesis in our country. Early identification of poor prognostic factors is 
essential to predict the outcome of the disease in affected population. 
Our study was undertaken to study about the clinical and 
electrodiagnostic presentation in our south indian population and to correlate 
them with prognosis of the patients. 
Our study with a group of 50 patients showed that axonal variant of GBS 
with cranial nerve involvement, dysautonomia, dependence on mechanical 
ventilation and decreased CMAP on nerve conduction study to be associated 
with higher mortality and morbidity in comparision to other parameters. 
Age of the patients, sex distribution, month of admission, preceding 
events of respiratory and gastrointestinal infections were not associated with 
mortality and morbidity of the patients with minimal effect of preceding 
infections on recovery of the patients. 
Early identification of the severely affected group with the above 
mentioned adverse clinical and electrodiagnostic profile can be helpful for 
prompt treatment, anticipation of complication and adequate rehabilitation of 
the patients and thereby attenuating the morbidity and mortality associated with 
the same 
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ANNEXURES 
 
II. PROFORMA 
Name : Patient ID No: 
Age/Sex :      Contact No: 
Date of admission:                                                  
Date of discharge: 
Occupation: 
COMPLAINTS 
o Weakness of lower limbs 
o Weakness of upper limbs 
o Numbness and paresthesia of limbs 
o Difficulty in walking 
o Difficulty in coordination 
o Difficulty in breathing and speaking 
o Difficulty in swallowing food 
o Difficulty in chewing food 
o Difficulty in blowing mouth 
o Deviation of angle of mouth 
o Nasal regurgitation 
o Difficulty in raising head from bed and mainting head posture 
o Difficulty of turning from side to side in bed 
o Diplopia 
o Excessive sweating 
o Bladder and bowel disturbance 
o Palpitations, giddiness and headache 
PAST HISTORY 
☐ Fever, URI, Diarrhoea, vaccination ☐ CAD, HTN, TYPE2DM 
☐ Kidney disease ☐ STROKE/TIA 
☐ Other Neurological disease 
PERSONAL HISTORY  
☐ Smoking 
☐ Alcohol intake 
GENERAL EXAMINATION 
BP: Lying: 
BP: Standing:                                        
Pulse: 
Weight:                                       
Single breath count:                                      
Resting heart rate:    
Systemic examination: 
CVS: 
RS: 
P/A: 
CNS: 
Higher mental functions 
Cranial nerves 
Spinomotor system- 
Bulk: 
Tone: 
Reflex: superficial and deep 
 Power-(Medical research council grading system) 
 Neck muscle weakness 
 Plantar 
 Neck stiffness 
 Sensory system 
Bladder and bowel: 
 Cerebellum 
Spine and cranium 
Disability scoring- Modified Disability Grading Scale for GBS (modified 
from Hughes RAC et al 1978.) 
 
                       
 
 
 
  
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
  
 
 
 PATIENT CONSENT FORM 
 
Study Title : Clinical and electrodiagnostic profile of Guillaine Barre 
syndrome and its correlation with early predictors of prognosis in 
a tertiary care centre. 
Study Centre : Rajiv Gandhi Government General Hospital, Chennai. 
Name :  
Age/Sex :  
Identification Number :  
Patient may check (☑) these boxes 
The details of the study have been provided to me in writing and explained to me in my 
own language  
I understand that my participation in the study is voluntary and that I am free to 
withdraw at any time without giving reason, without my legal rights being affected.  
I understand that sponsor of the clinical study, others working on the sponsor’s behalf, 
the ethical committee and the regulatory authorities will not need my permission to 
look at my health records, both in respect of current study and any further research 
that may be conducted in relation to it, even if I withdraw from the study I agree to 
this access. However, I understand that my identity will not be revealed in any 
information released to third parties or published, unless as required under the law. 
I agree not to restrict the use of any data or results that arise from this study.  
I agree to take part in the above study and to comply with the instructions given during 
the study and faithfully cooperate with the study team and to immediately inform 
the study staff if I suffer from any deterioration in my health or well being or any 
unexpected or unusual symptoms.  
I hereby consent to participate in this study.  
I hereby give permission to undergo complete clinical examination and diagnostic tests 
including hematological and biochemical tests.  
 
 
                                                                                                  
                                                                                                    
 Signature/thumb impression                                                    Signature of Investigator 
  Patients name and address                                                   Study Investigator’s Name: 
                                                                                                    Dr. KARTHIKA.R 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
KEY TO MASTER CHART 
A- PATIENT NUMBER 
B- AGE 
C- SEX 
D- ADMISSION MONTH 
E- DURATION OF STAY IN HOSPITAL 
F- PRECEDING EVENT RTI-RESPIRATORY INFECTION,AGE-
ACUTE GASTROENTERITIS 
G- PRESENTING SYMPTOM 
H- SENSORY INVOLVEMENT 
I- CRANIAL NERVE INVOLVENT 
J- DYSAUTONOMIA 
K- VENTILATOR DEPENDENCE 
L- DURATION OF MECHANICAL VENTILATION 
M- CSF PROTEIN IN MG% 
N- ALBUMINOCYTOLOGICAL DISSOCIATION 
O- ELECTRODIAGNOSTIC VARIANT D-DEMYELINATIVE, 
AMAN-ACUTE MOTOR AXONAL NEUROPATHY, AMSAN- 
ACUTE MOTOR SENSORY AXONAL NEUROPATHY 
P- DECREASED CMAP<10% OF LOWER LIMIT 
Q- TREATMENT GIVEN P-PLASMAPHARESIS, IVIG- IV 
IMMUNOGLOBULIN 
R- LATENCY FOR STARTING TREATMENT 
S- DEATH 
T- HUGHES DISABILITY GRADING AT DAY 15 
U- HUGHES DISABILITY GRADING AT DISCHARGE/DEATH 
V- COMPLETE RECOVERY 
W- RESIDUAL DEFICIT 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
